Provided by Tiger Trade Technology Pte. Ltd.

Zentalis Pharmaceuticals, LLC

3.71
-0.0500-1.33%
Post-market: 3.62-0.0900-2.43%17:25 EDT
Volume:863.80K
Turnover:3.17M
Market Cap:351.23M
PE:-1.89
High:3.74
Open:3.68
Low:3.55
Close:3.76
52wk High:6.95
52wk Low:1.21
Shares:94.67M
Float Shares:75.29M
Volume Ratio:1.45
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9591
EPS(LYR):-1.9100
ROE:-66.75%
ROA:-33.15%
PB:2.45
PE(LYR):-1.94

Loading ...

Zentalis Q1 net loss narrows to $35.35 million; operating loss improves to $37.86 million

Reuters
·
May 13

Zentalis initiates ASPENOVA Phase 3 trial of azenosertib in Cyclin E1-positive PROC

Reuters
·
May 13

Zentalis Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
May 08

BRIEF-Zentalis Pharmaceuticals Announces First Patient Dosed In Aspenova Phase 3 Trial Of Azenosertib In Patients With Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Reuters
·
May 05

Zentalis Pharmaceuticals Inc - Expects Denali Part 2 Topline Readout by Year-End 2026

THOMSON REUTERS
·
May 05

Zentalis grants 26,000 inducement stock options at $4.09 per share

Reuters
·
May 02

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 02

Zentalis Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
May 01

Zentalis to present phase 1b azenosertib-paclitaxel data in ovarian cancer at ASCO

Reuters
·
Apr 21

Zentalis to present azenosertib preclinical data in TNBC at AACR meeting

TIPRANKS
·
Apr 18

Zentalis presents azenosertib preclinical TNBC combination data at AACR 2026

Reuters
·
Apr 18

A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News

Simply Wall St.
·
Apr 13

What's Behind The Surge In Zentalis Stock?

Benzinga_recent_news
·
Apr 11

Zentalis Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 10

H.C. Wainwright Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
Apr 10

Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials

Reuters
·
Apr 09

Zentalis Pharmaceuticals Inc - Denali Part 2 Topline Readout Expected by Year-End 2026

THOMSON REUTERS
·
Apr 09

Zentalis Pharmaceuticals Announces 400Mg Qd 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Apr 09

BRIEF-Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 02

Zentalis grants inducement stock options for 36,000 shares to new hires

Reuters
·
Apr 02